Kevin Lee, Bicycle Therapeutics CEO (Bicycle)
Struggling Ionis licenses Bicycle Therapeutics' platform in a bid to develop drugs that can cross blood-brain barrier
Attempting to rebound from setbacks earlier this year, Ionis has enlisted a new partner in a quest to create drugs that can cross the blood-brain barrier. And the technology comes from a British biotech primarily known for its efforts into oncology.
The collaboration will see Ionis exclusively license a platform from Bicycle Therapeutics to develop oligonucleotides targeting the transferrin receptor 1, the companies announced Tuesday morning. Bicycle is nabbing $45 million upfront and an $11 million equity investment from Ionis.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters